Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hairy Cell Leukemia-Pipeline Review, H1 2015

Hairy Cell Leukemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hairy Cell Leukemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hairy Cell Leukemia-Pipeline Review, H1 2015', provides an overview of the Hairy Cell Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hairy Cell Leukemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hairy Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hairy Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hairy Cell Leukemia Overview 7

Therapeutics Development 8

Pipeline Products for Hairy Cell Leukemia-Overview 8

Pipeline Products for Hairy Cell Leukemia-Comparative Analysis 9

Hairy Cell Leukemia-Therapeutics under Development by Companies 10

Hairy Cell Leukemia-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Hairy Cell Leukemia-Products under Development by Companies 15

Hairy Cell Leukemia-Companies Involved in Therapeutics Development 16

Astellas Pharma Inc. 16

AstraZeneca PLC 17

Biogenomics Limited 18

F. Hoffmann-La Roche Ltd. 19

GlaxoSmithKline plc 20

Inbiopro Solutions Pvt. Ltd. 21

Incyte Corporation 22

MedImmune, LLC 23

Plexxikon Inc. 24

Hairy Cell Leukemia-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Combination Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AGS-67E-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

AZD-6738-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

IBPB-006IA-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

INCB-39110-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

INCB-40093-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

interferon alfa-2a (recombinant)-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

interferon alfa-2b-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

interferon alfa-2b (recombinant)-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

moxetumomab pasudotox-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

PLX-8394-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

vemurafenib-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Hairy Cell Leukemia-Recent Pipeline Updates 53

Hairy Cell Leukemia-Dormant Projects 62

Hairy Cell Leukemia-Discontinued Products 63

Hairy Cell Leukemia-Product Development Milestones 64

Featured News & Press Releases 64

May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 64

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

Number of Products under Development for Hairy Cell Leukemia, H1 2015 8

Number of Products under Development for Hairy Cell Leukemia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Comparative Analysis by Unknown Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Hairy Cell Leukemia-Pipeline by Astellas Pharma Inc., H1 2015 16

Hairy Cell Leukemia-Pipeline by AstraZeneca PLC, H1 2015 17

Hairy Cell Leukemia-Pipeline by Biogenomics Limited, H1 2015 18

Hairy Cell Leukemia-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19

Hairy Cell Leukemia-Pipeline by GlaxoSmithKline plc, H1 2015 20

Hairy Cell Leukemia-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 21

Hairy Cell Leukemia-Pipeline by Incyte Corporation, H1 2015 22

Hairy Cell Leukemia-Pipeline by MedImmune, LLC, H1 2015 23

Hairy Cell Leukemia-Pipeline by Plexxikon Inc., H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Assessment by Combination Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Hairy Cell Leukemia Therapeutics-Recent Pipeline Updates, H1 2015 53

Hairy Cell Leukemia-Dormant Projects, H1 2015 62

Hairy Cell Leukemia-Discontinued Products, H1 2015 63

List of Figures

Number of Products under Development for Hairy Cell Leukemia, H1 2015 8

Number of Products under Development for Hairy Cell Leukemia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc.

AstraZeneca PLC

Biogenomics Limited

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Inbiopro Solutions Pvt. Ltd.

Incyte Corporation

MedImmune, LLC

Plexxikon Inc.

Hairy Cell Leukemia Therapeutic Products under Development, Key Players in Hairy Cell Leukemia Therapeutics, Hairy Cell Leukemia Pipeline Overview, Hairy Cell Leukemia Pipeline, Hairy Cell Leukemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com